Regulating the immune system through tumor immunotherapy to defeat tumors is currently one of the most popular methods of tumor treatment. We previously found that the combinations of IL12, IL2 and GMCSF has superior antitumor activities. In this study, IL12IL2GMCSF fusion protein was produced from 293 cells transduced by expression lentiviral vector. IL12IL2GMCSF fusion protein was injected into canine tumors, and the efficacy was monitored to evaluate the potential of tumor immunotherapy. In 14 canines injected with IL12IL2GMCSF protein, 6 had a complete response (CR), 7 had a partial response (PR), and 1 had stable disease (SD). IL12IL2GMCSF fusion protein has great anti-tumor potential. Intratumoral injection of IL12IL2GMCSF can effectively treat tumors without severe adverse effects. It provides a promising immune therapeutics in canine cancers.

中文翻译：

---

肿瘤内注射IL12IL2GMCSF融合蛋白对犬肿瘤的治疗作用

通过肿瘤免疫疗法调节免疫系统以击败肿瘤是目前最流行的肿瘤治疗方法之一。我们先前发现IL12，IL2和GMCSF的组合具有优异的抗肿瘤活性。在这项研究中，IL12IL2GMCSF融合蛋白是由表达慢病毒载体转导的293细胞产生的。将IL12IL2GMCSF融合蛋白注入犬肿瘤，并监测疗效以评估肿瘤免疫疗法的潜力。在注射IL12IL2GMCSF蛋白的14只犬中，有6例具有完全缓解（CR），有7例具有部分缓解（PR），有1例患有稳定疾病（SD）。IL12IL2GMCSF融合蛋白具有巨大的抗肿瘤潜力。瘤内注射IL12IL2GMCSF可以有效治疗肿瘤而无严重不良反应。